pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['keynote,671', 'nsclc', 'pembro', 'sclc', 'lcsm,(-blcsm)', 'keynote-671']
at #asco2023, news from keynote-671 in early-stage #nsclc provides more evidence to support the #fda approval application for perioperative #pembrolizumab. #lcsm | 
Oncology news and insights from leading researchers and cancer centers.